Lotus Pharmaceutical Co (美時化學製藥) has received approval from Japan’s Pharmaceuticals and Medical Devices Agency for its generic version of blood cancer drug Revlimid (lenalidomide), boosting its shares by as much as 3.54 percent in early Taipei trading yesterday.
The approval was for 2.5mg and 5mg capsules of lenalidomide, which it jointly developed with Japan’s Fuji Pharma Corp, Lotus Pharmaceutical said in a regulatory filing on Tuesday.
Lotus Pharmaceutical was responsible for developing the lenalidomide formula — the company’s first high-value generic product in Japan, while Fuji Pharma ran local bioequivalence studies of the drug.
Photo: Reuters
With the approval, Lotus Pharmaceutical is to supply the finished product to Fuji Pharma for commercialization in Japan. The companies expect to launch the product in Japan this year.
Sales of Revlimid in Japan totaled about US$282 million last year, Lotus Pharmaceutical said, citing data from life sciences researcher Iqvia Institute.
As of the second quarter, only Osaka, Japan-based Sawai Pharmaceutical Co had obtained agency approval for lenalidomide, but its generic product has not yet been marketed in the Japanese market, Lotus Pharmaceutical said.
“Lotus and Fuji are among the first to market their product in Japan and gain a good market share there,” Capital Investment Management Corp (群益投顧) said in a note yesterday. “Lotus received 16 approvals for its generic products worldwide in the second quarter, which is a remarkable achievement and will gradually contribute to its revenue and royalty income in the future.”
Lotus Pharmaceutical shares surged in early morning trading yesterday before retreating to close up 1.71 percent at NT$268.
Capital Investment gave Lotus Pharmaceutical a “buy” rating with a 12-month target price of NT$295.
Lotus Pharma’s net profit more than tripled to NT$1.27 billion (US$39.82 million) in the second quarter, up 286 percent from NT$327.67 million in the same period last year, the company said on Tuesday.
That translated into earnings per share (EPS) of NT$4.85, the best second-quarter performance in its history.
In the first half of the year, EPS totaled NT$9.43, up 217 percent year-on-year, it said.
Lotus Pharma’s cumulative revenue in the first seven months totaled NT$11.25 billion, up 58.16 percent from the same period last year, company data showed.
With better business prospects, the company projected annual revenue growth of 13 to 15 percent for this year, higher than its previous estimate of 7 to 10 percent, while gross margin is expected to reach 55 percent, compared with 50 percent in its earlier forecast.
AI REVOLUTION: The event is to take place from Wednesday to Friday at the Taipei Nangang Exhibition Center’s halls 1 and 2 and would feature more than 1,100 exhibitors Semicon Taiwan, an annual international semiconductor exhibition, would bring leaders from the world’s top technology firms to Taipei this year, the event organizer said. The CEO Summit is to feature nine global leaders from Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), ASE Technology Holding Co (ASE, 日月光投控), Applied Materials Inc, Google, Samsung Electronics Co, SK Hynix Inc, Microsoft Corp, Interuniversity Microelectronic Centre and Marvell Technology Group Ltd, SEMI said in a news release last week. The top executives would delve into how semiconductors are positioned as the driving force behind global technological innovation amid the artificial intelligence (AI) revolution, the organizer said. Among them,
Demand for artificial intelligence (AI) chips should spur growth for the semiconductor industry over the next few years, the CEO of a major supplier to Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) said, dismissing concerns that investors had misjudged the pace and extent of spending on AI. While the global chip market has grown about 8 percent annually over the past 20 years, AI semiconductors should grow at a much higher rate going forward, Scientech Corp (辛耘) chief executive officer Hsu Ming-chi (許明琪) told Bloomberg Television. “This booming of the AI industry has just begun,” Hsu said. “For the most prominent
Former Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) chairman Mark Liu (劉德音) yesterday warned against the tendency to label stakeholders as either “pro-China” or “pro-US,” calling such rigid thinking a “trap” that could impede policy discussions. Liu, an adviser to the Cabinet’s Economic Development Committee, made the comments in his keynote speech at the committee’s first advisers’ meeting. Speaking in front of Premier Cho Jung-tai (卓榮泰), National Development Council (NDC) Minister Paul Liu (劉鏡清) and other officials, Liu urged the public to be wary of falling into the “trap” of categorizing people involved in discussions into either the “pro-China” or “pro-US” camp. Liu,
Minister of Economic Affairs J.W. Kuo (郭智輝) yesterday said Taiwan’s government plans to set up a business service company in Kyushu, Japan, to help Taiwanese companies operating there. “The company will follow the one-stop service model similar to the science parks we have in Taiwan,” Kuo said. “As each prefecture is providing different conditions, we will establish a new company providing services and helping Taiwanese companies swiftly settle in Japan.” Kuo did not specify the exact location of the planned company but said it would not be in Kumamoto, the Kyushu prefecture in which Taiwan Semiconductor Manufacturing Company (TSMC, 台積電) has a